ABN: 85 001 422 895 Media Release Embargo: 6.30pm, 11 December 2014 A/PROF GUILLAUME LESSENE WINS INAUGURAL DR JOHN DIXON HUGHES MEDICAL RESEARCH INNOVATION MEDAL [SYDNEY,NSW] – Dr John Dixon Hughes OAM announced today that A/Prof Guillaume Lessene has been hailed as the inaugural recipient of the National Foundation for Medical Research and Innovation’s (NFMRI) Dr John Dixon Hughes Medal for Medical Research Innovation. A/Prof Lessene was recognized at the NFMRI Awards in Sydney for having broken boundaries in his research to discover and develop drugs that target apoptosis, and for his links with industry in commercialising products for clinical use. Apoptosis is a form of programmed “cell suicide” that normal cells undergo, but that some cancer cells have developed ways to resist. Having been nominated by pre-eminent peers, A/Prof Lessene’s discoveries have led to a potential new anti-cancer agent that could trick cancer cells into committing suicide. The new class of drugs, the so-called ‘BH3-mimetics’ could have a profound impact on cancer therapy. • • A/Prof Guillaume Lessene’s research into apoptosis (cell suicide) has contributed to the discovery of a new class of drugs called BH3-mimetics. Some BH3-mimetics have already demonstrated profound responses in patients with blood cancers. Inaugural award includes $50,000 prize to support A/Prof Lessene’s research The inaugural award came with a prize of $50,000 to further supplement A/Prof Lessene’s research at the Walter and Eliza Hall Institute of Medical Research into new and improved cancer therapies. “The clinical potential from this new class of drugs is extraordinary,” says Professor Doug Hilton, director of the Walter and Eliza Hall Institute. He adds, “Other drugs in this class have already demonstrated profound responses in patients with blood cancers. We are very excited about the potential of the new agents being developed by Guillaume and his team for treating cancers that are resistant to cell death.” Professor Hilton stressed that while the impacts of A/Prof Lessene’s and his team’s work was already playing out in both the clinical and commercial spaces, it would take decades for the full implications to be realised. Dr Noel Chambers, CEO of the NFMRI noted that A/Prof Lessene was a model example of what could be achieved when a strong vision and goals were fueled with determination and supplemented by collaboration. “A/Prof Lessene’s achievements demonstrate the type of impact and research mindset that the Foundation has set out to support. The next award will be presented in 2016. MORE About the Awards The NFMRI awards the Dr John Dixon Hughes Medal for Medical Research Innovation every two years to researcher under the age of 45 who is nominated by his or her peers for outstanding contribution towards the development and advancement of a biomedical innovation related to the nature, prevention, diagnosis, treatment and incidence of disease and other health problems that have a significant impact on the health of humans. The award is named in honour of the NFMRI’s longest-standing Trustee and Chairman of the Research Advisory Committee, Dr John Dixon Hughes OAM, who was a founding member of the Foundation in 1977 and remains an active, dedicated and passionate board member to this. About NFMRI The NFMRI’s primary objective is to support innovative areas of research to help benefit mankind through the prevention or eradication of diseases. By focusing on advancing innovations and enabling collaborations, the Foundation aims to address the critical gaps that prevent industry uptake to bring diagnostics, devices, vaccines, tools and medicines into the hands of those in need in the community. The Foundation also seeks to partner with researchers and donors to identify, evaluate and support innovative quality research projects with identified impact objectives. NFMRI’s culture is one where we look to make a social investment in medical research. By partnering with researchers to provide support and knowledge, we aim to maximise the social returns from our grants. CONTACT: For further information or for interviews, please contact: NFMRI Dr Noel Chambers, Chief Executive Officer M: 0412 357 893 E: [email protected] GPO Box 9986 Sydney, NSW 2001 END
© Copyright 2024 Paperzz